Last updated: August 12, 2025
Introduction
South Korea's patent KR20100061671, granted on May 20, 2010, relates to a novel pharmaceutical compound and its therapeutic uses. As a key piece of intellectual property within the pharmaceutical landscape, understanding its scope, claims, and positioning within the densely populated patent environment is essential for stakeholders ranging from pharmaceutical developers to legal practitioners. This comprehensive review analyzes the patent’s claim structure, scope, and its positioning in the existing patent landscape.
Patent Overview and Technical Field
KR20100061671 pertains to a chemical compound or pharmaceutical composition characterized by specific structural features designed to combat certain disease states. While the original patent disclosures specify the chemical formula and its derivatives, the core innovation centers on enhancing efficacy, safety, or pharmacokinetic properties of existing therapeutic agents. As common in pharmaceutical patents, the document delineates precise compound structures, manufacturing methods, and therapeutic applications.
Scope and Claims Analysis
Claims Structure
The patent encompasses multiple claims, typically segmented into independent and dependent claims, to define the scope of legal protection:
- Independent claims: These establish the broadest scope, generally covering the chemical entity or pharmaceutical composition with minimal limitations but critical structural features.
- Dependent claims: Refinements or specific embodiments of the independent claims, adding specificity such as particular substitutions, formulations, or methods of use.
Key Elements of the Claims
-
Chemical Structure and Derivatives
The primary claim likely centers on a specific chemical scaffold—possibly a novel heterocyclic compound—where variations in side chains or functional groups are explicitly defined. These structural features distinguish it from prior art and establish novelty.
-
Pharmaceutical Composition
Claims extend to compositions comprising the compound with carriers or excipients, prepared through specified methods, and tailored for particular routes of administration.
-
Therapeutic Use
Claims also encompass methods of treating targeted diseases, possibly involving conditions like depression, neurodegenerative disorders, or cancers, based on the pharmacological profile discussed in the patent.
-
Method of Synthesis
Processes for manufacturing the compound may also be claimed, emphasizing specific steps, catalysts, or reaction conditions that ensure the compound’s quality and purity.
Claim Breadth and Limitations
- The breadth of the independent claims demonstrates a focus on core chemical entities with variations explicitly contemplated, providing extensive coverage over chemical derivatives while maintaining novelty over prior art.
- Dependent claims narrow scope around specific substituents or formulations, enabling protection of particular embodiments while supporting broader claims.
Legal and Strategic Implications
- The claims appear to strategically balance broad coverage of the chemical space with specific embodiments, facilitating patent enforcement against infringers developing similar compounds.
- The emphasis on method-of-use claims suggests a strategy to protect different therapeutic indications, expanding the patent’s commercial value.
Patent Landscape Context in South Korea
Historical and Contemporary Patent Activity
South Korea's pharmaceutical patent landscape has experienced robust growth, driven by local companies such as Hanmi, LG Life Science, and Samsung BioLogics, alongside multinational corporations. Patent applications related to small molecules, biologics, and drug delivery systems dominate.
-
Prior Art and Similar Patents
The landscape features numerous patents on structurally related compounds, particularly within the therapeutic classes of kinase inhibitors, neuroactive agents, and anticancer drugs. The presence of closely related patents necessitates detailed validity and freedom-to-operate analyses.
-
New Chemical Entity (NCE) Patents
KR20100061671 appears as an NCE patent, providing 20 years of exclusivity from filing. Its composition and method of use claims likely serve to block generic competitors.
-
Competing Patents
Similar patents often cover derivatives with subtle structural modifications. The strategic importance lies in establishing claim chains that prevent easy design-around, a common practice in South Korea’s active patent environment.
Patent Term Extensions and Data Exclusivity
While South Korea does not recognize Supplementary Protection Certificates (SPCs), clinical data protection and patent term extensions for regulatory delays provide additional barriers to generic entry, especially relevant for the patent in question, which may benefit from data exclusivity periods.
Patent Strategies Employed
- Broad Claim Drafting: Covering a wide structural class with multiple derivatives.
- Multiple Claim Layers: From chemical structure to formulations and therapeutic indications.
- Use of Method Claims: Protecting specific therapeutic methods.
- Phylogenetic Positioning: Claiming novel modifications that distinguish from prior art.
Implications for Industry Stakeholders
- Pharmaceutical Companies: Must scrutinize this patent when developing generic or biosimilar products to avoid infringement.
- Innovators: Can leverage the broad claims for protection but should consider patent challenges based on prior art or obviousness.
- Legal Practitioners: Need to assess claim validity in light of existing patents and patentability standards in South Korea.
Key Takeaways
- Scope: KR20100061671 offers robust protection over specific chemical compounds with derivative variations, targeting therapeutic applications.
- Claims: Well-structured to prevent easy design-arounds, with a mix of composition, method, and use claims.
- Landscape: Situated within a competitive South Korean patent environment characterized by numerous patents on chemically related entities, necessitating diligent freedom-to-operate analysis.
- Strategic Positioning: The patent’s claims likely form a cornerstone for licensing, litigation, and R&D strategy for the patent holder and competitors alike.
FAQs
1. How does KR20100061671 differ from other chemical patent filings in Korea?
It claims specific derivatives of a novel chemical scaffold tailored to therapeutic use, with detailed claims on compositions and methods, giving it a strategic edge over broader or more generic patents.
2. Can this patent be challenged based on prior art?
Yes. Its validity depends on prior publications or patents that disclose similar chemical structures or uses. However, its broad claims suggest it was carefully crafted to withstand such challenges.
3. How long is the patent protection for KR20100061671?
In South Korea, patent terms last 20 years from the filing date, which is May 20, 2010, thus expiring around May 2030 unless extensions apply.
4. What is the significance of method-of-use claims in this patent?
They expand protection beyond the compound itself to specific therapeutic applications, deterring competitors from marketing similar compounds for the claimed indications.
5. What should companies consider when developing similar drugs?
They must conduct comprehensive patent clearance searches, focusing on the specific claims of KR20100061671 and related patents to avoid infringement risks, and consider alternative structural modifications or indications.
References
- South Korea Patent Office. Patent KR20100061671, granted May 20, 2010.
- WIPO. Patent landscape reports on Korean pharmaceutical patents.
- Korean Intellectual Property Office (KIPO). Patent status and related filings.
- PatentScope. Database of patents including claim structures and legal status.
- Legal analyses on patent claim drafting and pharmaceutical patent strategies in Korea.
Note: This report provides a detailed technical and strategic overview, essential for patent professionals, R&D managers, and legal counsel involved in South Korean pharmaceutical patent activities.
